#United States #New York #Pomerantz LLP #Fulgent Genetics #FLGT

Pomerantz Law Firm Investigates Fulgent Genetics, Inc.

On June 1, 2025, the Pomerantz Law Firm announced an investigation concerning potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). This inquiry centers on allegations of securities fraud or other unlawful business practices carried out by the Company and certain executives. Potential investors are encouraged to contact Pomerantz for more information.

Recent Developments

The investigation was triggered following a significant disclosure made by Fulgent during its annual report filed with the U.S. Securities and Exchange Commission on February 28, 2025. It was revealed that the U.S. Department of Justice had issued a civil investigative demand concerning possible false claims submitted under the Uninsured Program.

This news had immediate repercussions on Fulgent's stock price, causing a decrease of $0.41 per share, equivalent to a 2.61% drop, within two trading sessions, bringing the stock down to $15.28 per share by March 3, 2025. This decline has raised concerns among investors regarding the potential impact of legal scrutiny on the company's prospects.

The Role of Pomerantz LLP

Pomerantz LLP is well-known for its expertise in handling corporate and securities class litigation cases. The law firm, with a long-standing reputation in the field, was established by Abraham L. Pomerantz, who was notable for pioneering securities class actions. Over its 85-plus years of operation, the firm has successfully secured numerous damages awards for shareholders and remains dedicated to defending victims of corporate misconduct.

Investors wishing to seek more information about their legal rights concerning the ongoing investigation into Fulgent Genetics are advised to reach out to the firm directly. Pomerantz aims to ensure that affected investors receive the necessary representation in any emerging litigation associated with this case.

Conclusion

As Fulgent Genetics continues to navigate the legal landscape, its investors face uncertainty regarding the outcome of these developments. The ongoing investigation by Pomerantz LLP not only highlights the potential risks of being involved with publicly traded companies facing legal scrutiny but also serves as a reminder for investors to remain vigilant and informed about the companies they invest in.

Fulgent's situation emphasizes the importance of corporate transparency and accountability, as legal challenges can significantly affect stock value and investor confidence. Stakeholders are encouraged to monitor this situation closely and explore their options should they be impacted by these allegations.